Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alo

Cosmo Pharmaceuticals N.V. / Key word(s): StudyCosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia 29.06.2023 / 06:15 GMT/BSTDublin, Ireland – June 29, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the beginning of the phase I...

Related Keywords

Poland ,Germany ,Dublin ,Ireland ,Japan ,Paris ,France General ,France ,Spain ,Georgia ,United States ,Geneva ,Genè ,Switzerland ,Italy ,United Kingdom ,Diana Harbort ,Hazel Winchester ,Clascoterone Cortexolone ,Medtronic ,Cosmo Pharmaceuticalsnv Key ,Cosmo Pharmaceuticals ,Cosmo Dermatology Division ,Target Area Hair Count ,Patient Reported Outcome ,Dermatology Division ,Epidemiology Forecast ,Year Results ,London Healthcare Conference ,Communication European Midcap Event ,Hair Growth Assessment ,